Vertex Pharmaceuticals (NASDAQ:VRTX) Shares Up 9.9% After Analyst Upgrade

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shot up 9.9% during trading on Tuesday after Morgan Stanley raised their price target on the stock from $570.00 to $596.00. Morgan Stanley currently has an overweight rating on the stock. Vertex Pharmaceuticals traded as high as $507.00 and last traded at $506.41. 1,315,084 shares changed hands during trading, a decline of 10% from the average session volume of 1,460,381 shares. The stock had previously closed at $460.87.

Several other analysts also recently issued reports on the company. Cantor Fitzgerald restated an “overweight” rating and set a $590.00 price objective on shares of Vertex Pharmaceuticals in a report on Friday, February 13th. Evercore lifted their target price on shares of Vertex Pharmaceuticals from $475.00 to $530.00 and gave the stock an “outperform” rating in a research report on Friday, January 23rd. Citigroup boosted their price target on shares of Vertex Pharmaceuticals from $575.00 to $585.00 and gave the company a “buy” rating in a report on Tuesday. Leerink Partners raised their price objective on shares of Vertex Pharmaceuticals from $456.00 to $525.00 and gave the stock an “outperform” rating in a research note on Monday, December 29th. Finally, Wolfe Research upgraded shares of Vertex Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $548.00 price objective on the stock in a research report on Tuesday, January 6th. Twenty-three investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $551.77.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 4,500 shares of the company’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $474.99, for a total value of $2,137,455.00. Following the transaction, the executive vice president owned 42,293 shares in the company, valued at approximately $20,088,752.07. This represents a 9.62% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Mark E. Bunnage sold 2,021 shares of the stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $460.43, for a total transaction of $930,529.03. Following the completion of the sale, the executive vice president owned 12,914 shares of the company’s stock, valued at approximately $5,945,993.02. The trade was a 13.53% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 91,156 shares of company stock worth $42,845,497 over the last ninety days. 0.20% of the stock is currently owned by corporate insiders.

Trending Headlines about Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex reported positive Week‑36 interim results from the Phase 3 RAINIER trial for povetacicept — the study met its primary and all secondary endpoints, supporting the drug’s potential as a best‑in‑class treatment for IgA nephropathy. Vertex Announces Positive Week 36 Interim Analysis Results
• Positive Sentiment: News outlets note the trial win as a major validation — coverage emphasizes the result as a “key test” passed and calls the data “remarkable,” boosting confidence in Vertex’s kidney‑disease strategy. Vertex passes key test In quest to treat kidney diseases
• Positive Sentiment: Interim efficacy metrics cited in coverage (e.g., ~52% reduction in proteinuria) raise hopes for meaningful clinical benefit and potential for an accelerated FDA filing pathway, increasing the drug’s peak‑sales and valuation assumptions. VRTX Stock Gains on Upbeat Interim Data From Kidney Disease Drug Study
• Positive Sentiment: Multiple brokerages responded quickly with higher price targets and fresh buy/outperform ratings (examples: Morgan Stanley, BofA, Oppenheimer, HC Wainwright, Citi, Jefferies, BMO and others), reflecting analysts modeling substantial upside from povetacicept. Benzinga — analyst price target coverage
• Neutral Sentiment: Vertex presented at the Leerink Global Healthcare Conference (transcript available), which may provide additional detail on timing, filing plans and commercial strategy but is less market‑moving than the trial headlines. Vertex Presents at Leerink Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Market commentary and aggregator pieces (Barron’s, Yahoo, Investopedia, TipRanks) are amplifying the newsflow — helpful for liquidity and momentum but reflecting the same core trial announcement rather than new independent data. Investopedia — trial results coverage

Institutional Trading of Vertex Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of VRTX. Chesapeake Asset Management LLC raised its stake in shares of Vertex Pharmaceuticals by 110.0% during the 3rd quarter. Chesapeake Asset Management LLC now owns 63 shares of the pharmaceutical company’s stock worth $25,000 after purchasing an additional 33 shares in the last quarter. Motiv8 Investments LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 4th quarter valued at about $26,000. Colonial Trust Co SC grew its stake in shares of Vertex Pharmaceuticals by 118.8% in the 3rd quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 38 shares in the last quarter. Swiss RE Ltd. acquired a new position in Vertex Pharmaceuticals in the fourth quarter worth approximately $28,000. Finally, Eagle Bay Advisors LLC bought a new position in Vertex Pharmaceuticals during the fourth quarter valued at approximately $29,000. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Stock Up 8.3%

The stock has a market cap of $126.80 billion, a P/E ratio of 32.56 and a beta of 0.31. The firm’s 50-day moving average is $468.41 and its two-hundred day moving average is $436.53.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 EPS for the quarter, missing the consensus estimate of $5.05 by ($0.02). The business had revenue of $3.19 billion during the quarter, compared to the consensus estimate of $3.18 billion. Vertex Pharmaceuticals had a return on equity of 24.30% and a net margin of 32.94%.The business’s revenue was up 9.5% on a year-over-year basis. During the same period in the prior year, the firm earned $3.98 earnings per share. Analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.